drugset
drugset / Trial / NCT02253550

Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection

NCT02253550 ↗

Phase 2 Completed 30 enrolled Peter J. Ruane, M.D., Inc. Janssen Scientific Affairs, LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.

Timeline

Start
2014-10
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Simeprevir Small molecule — —
Subject Sofosbuvir Small molecule — —

Indications

chronic hepatitis C virus infection